FENC

Fennec Pharmaceuticals Inc.

7.01 USD
+0.31 (+4.63%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Fennec Pharmaceuticals Inc. stock is down -23.89% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 53.85% of the previous 12 May’s closed higher than April. 100% of analysts rate it a buy.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

  • Craig-Hallum
    Wed May 15, 13:52
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 15, 07:08
    buy
    confirm